Pemphigus Vulgaris Market Positioned for Growth Through 2034, DelveInsight Finds | Roche, Cabaletta Bio and Others

The Pemphigus Vulgaris (PV) market was valued at approximately USD 340 million and is projected to grow at a robust CAGR during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Pemphigus Vulgaris landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Pemphigus Vulgaris market is increasingly guided by targeted immunotherapy strategies. Rituximab (anti-CD20 monoclonal antibody) represents a highly lucrative therapeutic segment, with the anti-CD20 therapy segment capturing significant market share in 2025, driven by proven B-cell depletion properties and clinical evidence supporting disease remission across moderate-to-severe pemphigus vulgaris applications.

DelveInsight's report, "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast- 2034," provides a comprehensive analysis of the Pemphigus Vulgaris landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Pemphigus Vulgaris market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, visit Pemphigus Vulgaris Market Forecast

Some of the key facts of the Pemphigus Vulgaris Market Report:

• Key Pemphigus Vulgaris Companies: Roche, Cabaletta Bio and others
• Key Pemphigus Vulgaris Therapies: Rituxan (rituximab), PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others
• The Pemphigus Vulgaris market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pemphigus Vulgaris pipeline products will significantly revolutionize the Pemphigus Vulgaris market dynamics.

Pemphigus Vulgaris Overview

Pemphigus Vulgaris (PV) is a rare autoimmune disorder characterized by painful blisters and erosions on the skin and mucous membranes. It occurs when the immune system mistakenly attacks proteins that hold skin cells together, leading to severe dermatological issues. Without proper treatment, pemphigus vulgaris can lead to significant morbidity and complications, including mucocutaneous involvement. Risk factors include genetic predisposition, environmental triggers, and individual susceptibility. Early detection through serological testing and specialized dermatological evaluation improves patient outcomes and enables timely therapeutic intervention.

Key Trends in Pemphigus Vulgaris Therapeutics Market

• Rising Adoption of Rituximab and Anti-CD20 Therapies: Increasing use of rituximab as first-line treatment in moderate-to-severe pemphigus vulgaris with established clinical evidence supporting disease remission and corticosteroid-sparing capabilities
• Immunotherapy Expansion: Growing uptake of biologic therapies and targeted B-cell depletion approaches for enhanced disease control and sustained remission induction
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics and serological testing enabling personalized treatment strategies and better patient stratification
• Pipeline Innovation: Development of next-generation biologic therapies, JAK inhibitors, and emerging immunomodulatory agents to address treatment resistance and unmet clinical needs
• Biosimilar Market Development: Rising availability of cost-effective rituximab biosimilar alternatives improving treatment accessibility across diverse healthcare settings
• Digital Health Integration: Use of telemedicine, patient registries, and remote monitoring to optimize treatment outcomes and enhance patient quality of life

Pemphigus Vulgaris Epidemiology

The report provides a comprehensive analysis of the Pemphigus Vulgaris prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease severity classifications. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Pemphigus Vulgaris and plan targeted interventions, research, and treatment strategies.

In 2023, the United States reported more than 75% of the diagnosed prevalent cases of Pemphigus Vulgaris across 7MM. In the United States, individuals aged 60-69 years account for the highest number of Pemphigus Vulgaris cases in 2023. Across the 7MM, the prevalence of females is higher than males in Pemphigus Vulgaris.

Furthermore, Pemphigus Vulgaris epidemiology data demonstrates significant regional variations. The Pemphigus Vulgaris market analysis across major markets reveals diverse disease burden and patient demographics, supporting the need for region-specific treatment strategies and healthcare resource allocation.

Pemphigus Vulgaris Epidemiology Segmentation

The Pemphigus Vulgaris market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed prevalent cases of Pemphigus Vulgaris
• Gender-specific cases of Pemphigus Vulgaris
• Age-specific cases of Pemphigus Vulgaris
• Severity-specific cases of Pemphigus Vulgaris
• Total Treated cases of Pemphigus Vulgaris

Download the report to understand which factors are driving Pemphigus Vulgaris epidemiology trends @ Pemphigus Vulgaris Epidemiology Forecast

Recent Development In The Pemphigus Vulgaris Treatment Landscape

• In November 2025, Cabaletta Bio presented new RESET‑PV Phase 1/2 data for rese‑cel (CABA‑201, CD19 CAR‑T) in pemphigus vulgaris at the 2025 ESGCT congress, showing complete B‑cell depletion in 2 of 3 low‑dose, no‑preconditioning patients with early clinical responses and a generally well‑tolerated profile

Pemphigus Vulgaris Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pemphigus Vulgaris market or expected to get launched during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pemphigus Vulgaris Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pemphigus Vulgaris Therapies and Key Companies

• Rituxan (rituximab): Roche
• PRN1008: Principia Biopharma
• KC706: Kezar Life Sciences
• Efgartigimod PH20 SC: argenx
• mRNA-1273: Moderna Therapeutics
• Cabaletta Bio pipeline candidates: Cabaletta Bio

To know more about Pemphigus Vulgaris companies working in the treatment market, visit @ Pemphigus Vulgaris Clinical Trials and Therapeutic Assessment

Pemphigus Vulgaris Market Drivers

• Increasing prevalence of pemphigus vulgaris globally with improved diagnostic capabilities enabling early disease detection
• Growth of targeted biologic therapies, particularly anti-CD20 monoclonal antibodies, for B-cell mediated autoimmune responses
• Advancements in serological testing and molecular diagnostics enabling precision medicine approaches and improved patient stratification
• Rising healthcare expenditure and government initiatives supporting rare autoimmune disease treatment and research
• Expanding awareness and specialized dermatology center development through patient registries and clinical networks
• Development of combination therapies and emerging immunomodulatory agents improving treatment efficacy and tolerability
• Increasing availability of biosimilar rituximab alternatives reducing treatment costs and improving patient access
• Enhanced reimbursement coverage and healthcare insurance expansion supporting biologic therapy adoption

Pemphigus Vulgaris Market Barriers

• High cost of biologic therapies limiting patient access in resource-limited healthcare systems
• Complex disease mechanisms and heterogeneous patient responses requiring personalized treatment approaches
• Resistance development and treatment failure in subset of patients reducing long-term therapy efficacy
• Limited disease awareness and diagnostic delays in emerging markets affecting timely intervention
• Side effects and safety concerns associated with immunosuppressive therapies affecting treatment adherence
• Variability in clinical presentation and severity affecting standardized treatment protocol development
• Regulatory challenges and lengthy approval processes for novel therapeutics delaying market access

Scope of the Pemphigus Vulgaris Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Pemphigus Vulgaris Companies: Roche, Cabaletta Bio and others
• Key Pemphigus Vulgaris Therapies: Rituxan (rituximab), PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, mRNA-1273, and others
• Pemphigus Vulgaris Therapeutic Assessment: Pemphigus Vulgaris current marketed and Pemphigus Vulgaris emerging therapies
• Pemphigus Vulgaris Market Dynamics: Pemphigus Vulgaris market drivers and Pemphigus Vulgaris market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pemphigus Vulgaris Unmet Needs, KOL's views, Analyst's views, Pemphigus Vulgaris Market Access and Reimbursement

Discover more about therapies set to grab major Pemphigus Vulgaris market share @ Pemphigus Vulgaris Treatment Market